Point72 Asset Management L.P. Has $42.03 Million Stock Holdings in Glaukos Co. (NYSE:GKOS)

Point72 Asset Management L.P. lessened its holdings in shares of Glaukos Co. (NYSE:GKOS) by 26.9% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 280,312 shares of the medical instruments supplier’s stock after selling 103,084 shares during the period. Point72 Asset Management L.P. owned 0.51% of Glaukos worth $42,030,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of the business. Quadrant Capital Group LLC boosted its holdings in Glaukos by 3.3% during the fourth quarter. Quadrant Capital Group LLC now owns 2,300 shares of the medical instruments supplier’s stock worth $345,000 after buying an additional 73 shares during the last quarter. Mutual of America Capital Management LLC boosted its holdings in Glaukos by 1.1% during the fourth quarter. Mutual of America Capital Management LLC now owns 8,353 shares of the medical instruments supplier’s stock worth $1,252,000 after buying an additional 89 shares during the last quarter. HighTower Advisors LLC boosted its holdings in Glaukos by 2.8% during the fourth quarter. HighTower Advisors LLC now owns 3,298 shares of the medical instruments supplier’s stock worth $495,000 after buying an additional 91 shares during the last quarter. Louisiana State Employees Retirement System boosted its holdings in Glaukos by 0.4% during the fourth quarter. Louisiana State Employees Retirement System now owns 26,700 shares of the medical instruments supplier’s stock worth $4,003,000 after buying an additional 100 shares during the last quarter. Finally, Handelsbanken Fonder AB boosted its holdings in Glaukos by 0.7% during the fourth quarter. Handelsbanken Fonder AB now owns 14,700 shares of the medical instruments supplier’s stock worth $2,204,000 after buying an additional 100 shares during the last quarter. Institutional investors and hedge funds own 99.04% of the company’s stock.

Glaukos Price Performance

NYSE GKOS opened at $91.68 on Friday. The company has a quick ratio of 4.71, a current ratio of 5.54 and a debt-to-equity ratio of 0.19. Glaukos Co. has a 12-month low of $77.10 and a 12-month high of $163.71. The company has a market capitalization of $5.24 billion, a PE ratio of -31.94 and a beta of 0.83. The firm’s 50 day moving average is $93.95 and its 200-day moving average is $126.28.

Glaukos (NYSE:GKOS) last announced its quarterly earnings data on Wednesday, April 30th. The medical instruments supplier reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.33) by $0.11. The company had revenue of $106.66 million during the quarter, compared to analysts’ expectations of $102.78 million. Glaukos had a negative return on equity of 16.53% and a negative net margin of 39.04%. Glaukos’s revenue for the quarter was up 24.6% compared to the same quarter last year. During the same quarter last year, the company earned ($0.70) EPS. Equities research analysts anticipate that Glaukos Co. will post -1.08 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on GKOS. Mizuho cut their target price on shares of Glaukos from $200.00 to $175.00 and set an “outperform” rating on the stock in a report on Wednesday, April 16th. Wells Fargo & Company lowered shares of Glaukos from an “overweight” rating to an “equal weight” rating and cut their target price for the stock from $160.00 to $86.00 in a report on Thursday, May 1st. Needham & Company LLC lowered their price target on Glaukos from $176.00 to $115.00 and set a “buy” rating for the company in a report on Thursday, May 1st. Stephens lowered their price target on Glaukos from $140.00 to $115.00 and set an “overweight” rating for the company in a report on Friday, May 2nd. Finally, Morgan Stanley lowered their price target on Glaukos from $110.00 to $72.00 and set an “underweight” rating for the company in a report on Tuesday, May 6th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and ten have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $134.67.

Insider Activity

In other news, CFO Alex R. Thurman sold 1,520 shares of the company’s stock in a transaction dated Tuesday, March 25th. The shares were sold at an average price of $106.84, for a total value of $162,396.80. Following the sale, the chief financial officer now directly owns 53,431 shares of the company’s stock, valued at approximately $5,708,568.04. This represents a 2.77% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 5.80% of the stock is currently owned by insiders.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.